Zobrazeno 1 - 10
of 260
pro vyhledávání: '"Max S. Topp"'
Autor:
Bijal Shah, Ryan D. Cassaday, Jae H. Park, Roche Houot, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Kristen M. O’dwyer, Maria R. Baer, Gary J. Schiller, Mehrdad Abedi, Monique C. Minnema, Patrick Stiff, Lang Zhou, Tsveta Hadjivassileva, Rita Damico Khalid, Armin Ghobadi
Publikováno v:
HemaSphere, Vol 7, p e54499e3 (2023)
Externí odkaz:
https://doaj.org/article/7aed547152154c0faf9b4f2f5e348358
Autor:
Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O’Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H. Park, Marion Subklewe, Mehrdad Abedi, Monique C. Minnema, William G. Wierda, Daniel J. DeAngelo, Patrick Stiff, Deepa Jeyakumar, Jinghui Dong, Sabina Adhikary, Lang Zhou, Petra C. Schuberth, Imi Faghmous, Behzad Kharabi Masouleh, Roch Houot
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-11 (2022)
Abstract Background Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL) based on ZUMA-3 study r
Externí odkaz:
https://doaj.org/article/c6f5581c75904c159d9b64a730068459
Autor:
Nicola Gökbuget, Kristina Ihrig, Michael Stadler, Matthias Stelljes, Ahmet Elmaagacli, Michael Starck, Simon Raffel, Andrea Stoltefuss, Andreas Viardot, Karl-Anton Kreuzer, Daniela Heidenreich, Andrea Renzelmann, Ralph Wäsch, Max S. Topp, Barbara Ritter, Peter Reimer, Joachim Beck, Jörg Westermann, Knut Wendelin, Nael Alakel, Maher Hanoun, Hubert Serve, Dieter Hoelzer
Publikováno v:
Haematologica, Vol 108, Iss 7 (2023)
Cure rates in adult acute lymphoblastic leukemia (ALL) improved using pediatric-based chemotherapy and stem cell transplantation (SCT). However, limited data on the health condition of cured adults are available whereas pediatric data cannot be trans
Externí odkaz:
https://doaj.org/article/1d8dab2a15d6455985acc8405cfa5220
Autor:
Max S. Topp, Anthony S. Stein, Nicola Gökbuget, Heinz‐August Horst, Nicolas Boissel, Giovanni Martinelli, Hagop Kantarjian, Monika Brüggemann, Yuqi Chen, Gerhard Zugmaier
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2601-2610 (2021)
Abstract Background Blinatumomab is a BiTE® immuno‐oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL). Aims To assess the efficacy and safety of bl
Externí odkaz:
https://doaj.org/article/ebc78df1fadd4411a7df50baefc1a6c6
Autor:
Nicola Gökbuget, Hagop M. Kantarjian, Monika Brüggemann, Anthony S. Stein, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Leonard Heffner, Françoise Rigal-Huguet, Mark Litzow, Susan O'Brien, Gerhard Zugmaier, Shan Gao, Dirk Nagorsen, Stephen J. Forman, Max S. Topp
Publikováno v:
Blood Advances, Vol 3, Iss 20, Pp 3033-3037 (2019)
Abstract: Minimal residual disease (MRD), where leukemic cell levels are lower than the morphologic detection threshold, is the most important prognostic factor for acute lymphoblastic leukemia (ALL) relapse during first-line chemotherapy treatment a
Externí odkaz:
https://doaj.org/article/512b167390dd4c51bc5396468525468a
Autor:
Max S. Topp, Johannes Duell, Ana Maria Abajo Guijarro, Marielle Odin, Tina Nielsen, Anand Rajeswaran, Michael Wenger, Christelle Zundel, Aleksandra Bogucka-Fedorczuk, Tomasz Wrobel
Publikováno v:
Haematologica, Vol 105, Iss 5 (2020)
Externí odkaz:
https://doaj.org/article/2039a1fea2374e63a2eb4df348f6d122
Autor:
Anthony S. Stein, Richard A. Larson, Andre C. Schuh, William Stevenson, Ewa Lech-Maranda, Qui Tran, Zachary Zimmerman, William Kormany, Max S. Topp
Publikováno v:
Blood Advances, Vol 2, Iss 13, Pp 1522-1531 (2018)
Abstract: In the phase 3 TOWER study, blinatumomab demonstrated an overall survival benefit over standard-of-care chemotherapy (SOC) in adults with relapsed or refractory (r/r) Philadelphia chromosome–negative (Ph−) B-precursor acute lymphoblasti
Externí odkaz:
https://doaj.org/article/4cae2ee3265043889adec879c99a2cf3
Autor:
Dominik Kiem, Michael Leisch, Daniel Neureiter, Theresa Haslauer, Alexander Egle, Thomas Melchardt, Max S. Topp, Richard Greil
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 11, p 5449 (2021)
Background: Chimeric antigen receptor (CAR) T-cells are changing the therapeutic landscape of hematologic malignancies. Severe side effects include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), bu
Externí odkaz:
https://doaj.org/article/3b325efcd75349359dfd3f3a4d54116b
Autor:
Virginie Nägele, Andrea Kratzer, Gerhard Zugmaier, Chris Holland, Youssef Hijazi, Max S. Topp, Nicola Gökbuget, Patrick A. Baeuerle, Peter Kufer, Andreas Wolf, Matthias Klinger
Publikováno v:
Experimental Hematology & Oncology, Vol 6, Iss 1, Pp 1-14 (2017)
Abstract Background Blinatumomab has shown a remission rate of 69% in an exploratory single-arm, phase II dose-escalation study in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We evaluated changes in laborat
Externí odkaz:
https://doaj.org/article/c19fa123d37e404c918d9f88449602ec
Autor:
Nicola Gökbuget, Gerhard Zugmaier, Matthias Klinger, Peter Kufer, Matthias Stelljes, Andreas Viardot, Heinz A. Horst, Svenja Neumann, Monika Brüggemann, Oliver G. Ottmann, Thomas Burmeister, Dorothea Wessiepe, Max S. Topp, Ralf Bargou
Publikováno v:
Haematologica, Vol 102, Iss 4 (2017)
Externí odkaz:
https://doaj.org/article/01ce29e1989f4f4d84b31b21bf6b1ade